摘要
目的探究孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘的临床疗效。方法随机抽查法选取咳嗽变异性哮喘患儿96例,按照数字随机分组法分为治疗组和对照组各48例,治疗组采用孟鲁司特联合氨溴特罗治疗,对照组单独采用孟鲁司特钠治疗。比较两组患儿治疗效果,咳嗽缓解时间及肺功能改善情况。结果治疗组总有效率为95.83%,高于对照组总有效率75.00%,治疗后2周PEF变异率低于对照组,咳嗽缓解时间较对照组缩短,数据差异有统计学意义(P<0.05)。结论孟鲁司特联合氨溴特罗治疗儿童咳嗽变异性哮喘取得显著效果,能促进患儿较快恢复。
Objective To investigate the clinical efficacy of montelukast combined with ambroxol in children with cough variant asthma. Methods A total of 96 children with cough variant asthma were randomly selected and randomly divided into treatment group and control group. 48 cases were treated with montelukast and ambroxol in the treatment group, and montelukast alone in the control group. The treatment group was treated with montelukast plus ambroxol. The control group was treated with montelukast sodium alone. The therapeutic effect, cough relief time and improvement of pulmonary function were compared between the two groups. Results The total effective rate of the treatment group was 95.83%, higher than the total effective rate of the control group of 75.00%. The PEF mutation rate was lower than the control group after 2 weeks of treatment, and the cough remission time was shorter than that of the control group. The difference was statistically significant（P〈0.05）. Conclusion Montelukast combined with ambroxol has a significant effect on children with cough variant asthma and can promote rapid recovery in children.
作者
齐娜
刘爽
QI Na;LIU Shuang(Pediatrics Department,UAW General Hospital,Changchun Jilin 130011,China)
出处
《中国卫生标准管理》
2018年第12期112-114,共3页
China Health Standard Management
